MétaCan
Menu
Back to cohort
Record W4411312487 · doi:10.1016/j.phymed.2025.156968

Gegen Qinlian Tablets attenuate immune-related adverse events in NSCLC patients: A multi-center randomized controlled trial in China

2025· article· en· W4411312487 on OpenAlexfundno aff
Aolin Wang, Dongna Chen, Meng Yang, Yongming Zhang, Meng Liu, Xiaoyan Zhang, Yuan Li, Daiwei Liu, Yunliang Wang, Zhiqiang Cheng, Liya Li, Huijuan Cui

Bibliographic record

VenuePhytomedicine · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsnot available
FundersCapital Health
KeywordsMedicineAdverse effectRandomized controlled trialImmune systemOncologyCenter (category theory)Internal medicinePharmacologyImmunologyChemistry

Abstract

fetched live from OpenAlex

BACKGROUND: Immune related adverse events (irAEs) significantly compromise patients' quality of life and limit the application of immunotherapy. Gegen Qinlian Tablets (GQT), a classical Chinese herbal formula, have shown potential in mitigating irAEs. However, clinical evidence supporting the use of GQT as a synergy therapy for immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (NSCLC) remains insufficient. PURPOSE: To evaluate the efficacy and safety of GQT in reducing the incidence of irAEs in NSCLC with ICI treatment. STUDY DESIGN: A multi-center, open-label, randomized controlled trial. METHODS: Eligible patients were randomly assigned (1:1) to receive ICI plus chemotherapy plus GQT (GQT group) or ICI plus chemotherapy alone (control group). The primary outcome was the incidence and severity of irAEs. Secondary outcomes included objective response rate (ORR) and disease control rate (DCR). Serum levels of interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) were assessed at baseline and after treatment. RESULTS: From October 2022 to August 2024, 94 participants were randomized to the GQT group (n = 47) or the control group (n = 47) at four hospitals in China. The incidence of irAEs was significantly lower in the GQT group than in the control group [31.91 % (15/47) vs. 59.57 % (28/47), p = 0.007, 95 % CI: 0.137-0.741]. No patient in the GQT group experienced multi-systemic toxicity, whereas 3 patients in the control group did (3/28, 10.7 %). The median onset time of irAEs in the GQT group was 14.9 weeks, and was 8.7 weeks in the control group (p = 0.807). Among response-evaluable patients, the ORR was 48.9 % (0 CR, 23 PR) in the GQT group (n = 45), and 36.2 % (1 CR, 16 PR) in the control group (n = 43) (p = 0.211, 95 % CI: 0.686-3.725). IL-6 level significantly decreased after 3 treatment cycles in the GQT group (p < 0.001), potentially contributing to the reduced incidence of irAEs. CONCLUSION: GQT significantly reduced the incidence of irAEs and prolonged the median onset time of irAEs in patients with advanced NSCLC receiving ICI therapy. The observed effects may be associated with the downregulation of IL-6. GQT showed promise as a synergistic treatment that mitigated irAEs and might enhance the therapeutic efficacy of ICIs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0000.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.006
GPT teacher head0.275
Teacher spread0.269 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2025
Admission routes1
Has abstractno

Explore more

Same venuePhytomedicineSame topicCancer Immunotherapy and BiomarkersFrench-language works237,207